PHARMARON (03759) shares tumbled nearly 3% following a profit warning announcement. At press time, the stock dipped 1.89% to HK$18.70, registering a turnover of HK$65.84 million. On July 15, the company disclosed projected H1 2025 revenue between RMB6.33 billion and RMB6.50 billion, marking a 13%-16% annual growth. Net profit attributable to shareholders is forecasted at RMB679 million to RMB713 million, plunging 36%-39% year-over-year. Excluding non-recurring items, net profit climbed 34%-39% to RMB624 million-RMB648 million, while adjusted non-IFRS net profit attributable to shareholders rose 6%-11%.

Mid-range projections indicate Q2 2025 revenue expanded 13.11% annually, with non-recurring-adjusted net profit surging 23.33% and adjusted non-IFRS net profit up 13.67%. The firm attributed the shareholder net profit contraction primarily to diminished non-recurring gains, despite sustained improvement in core operations. This profit slump contrasts sharply with robust underlying business performance, highlighting the impact of extraordinary item volatility on bottom-line results.